Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
432.98
-7.96 (-1.81%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 427.00 - 435.16
52 week 325.35 - 543.55
Open 430.17
Vol / Avg. 990,334.00/799,072.00
Mkt cap 46.39B
P/E 43.46
Div/yield     -
EPS 9.96
Shares 105.24M
Beta 1.62
Inst. own 72%
Nov 8, 2017
Q3 2017 Regeneron Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Nov 8, 2017
Q3 2017 Regeneron Pharmaceuticals Inc Earnings Call - 8:30AM EST - Add to calendar
Sep 13, 2017
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
Sep 11, 2017
Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
Aug 3, 2017
Q2 2017 Regeneron Pharmaceuticals Inc Earnings Release
Aug 3, 2017
Q2 2017 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 26.38% 18.42%
Operating margin 37.43% 27.38%
EBITD margin - 29.53%
Return on average assets 19.53% 14.23%
Return on average equity 29.95% 22.10%
Employees 5,400 -
CDP Score - B

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 87
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply
Age: 44
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Robert J. Terifay Executive Vice President - Commercial
Age: 57
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 46
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 60
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. President and Chief Scientific Officer - Regeneron, Director
Age: 57
Bio & Compensation  - Reuters